144 related articles for article (PubMed ID: 24190099)
1. MPS II: adaptive behavior of patients and impact on the family system.
Needham M; Packman W; Rappoport M; Quinn N; Cordova M; Macias S; Morgan C; Packman S
J Genet Couns; 2014 Jun; 23(3):330-8. PubMed ID: 24190099
[TBL] [Abstract][Full Text] [Related]
2. Health-Related Quality of Life in Patients with MPS II.
Needham M; Packman W; Quinn N; Rappoport M; Aoki C; Bostrom A; Cordova M; Macias S; Morgan C; Packman S
J Genet Couns; 2015 Aug; 24(4):635-44. PubMed ID: 25395377
[TBL] [Abstract][Full Text] [Related]
3. Validation of the shortened Hunter Syndrome-Functional Outcomes for Clinical Understanding Scale (HS-FOCUS).
Mattera M; Vernon MK; Raluy-Callado M; Mikl J
Health Qual Life Outcomes; 2018 Nov; 16(1):209. PubMed ID: 30409228
[TBL] [Abstract][Full Text] [Related]
4. Diagnosis, quality of life, and treatment of patients with Hunter syndrome in the French healthcare system: a retrospective observational study.
Guffon N; Heron B; Chabrol B; Feillet F; Montauban V; Valayannopoulos V
Orphanet J Rare Dis; 2015 Apr; 10():43. PubMed ID: 25887606
[TBL] [Abstract][Full Text] [Related]
5. Cognitive, medical, and neuroimaging characteristics of attenuated mucopolysaccharidosis type II.
Yund B; Rudser K; Ahmed A; Kovac V; Nestrasil I; Raiman J; Mamak E; Harmatz P; Steiner R; Lau H; Vekaria P; Wozniak JR; Lim KO; Delaney K; Whitley C; Shapiro EG
Mol Genet Metab; 2015 Feb; 114(2):170-7. PubMed ID: 25541100
[TBL] [Abstract][Full Text] [Related]
6. The impact of Hunter syndrome (mucopolysaccharidosis type II) on health-related quality of life.
Raluy-Callado M; Chen WH; Whiteman DA; Fang J; Wiklund I
Orphanet J Rare Dis; 2013 Jul; 8():101. PubMed ID: 23837440
[TBL] [Abstract][Full Text] [Related]
7. Neurodevelopmental status and adaptive behavior of pediatric patients with mucopolysaccharidosis II: a longitudinal observational study.
Muenzer J; Burton BK; Amartino HM; Harmatz PR; Gutiérrez-Solana LG; Ruiz-Garcia M; Wu Y; Merberg D; Alexanderian D; Jones SA
Orphanet J Rare Dis; 2023 Nov; 18(1):357. PubMed ID: 37974184
[TBL] [Abstract][Full Text] [Related]
8. Analysis of cognitive ability and adaptive behavior assessment tools used in an observational study of patients with mucopolysaccharidosis II.
Yee KS; Wu Y; Harrington M; Waisbren SE
Orphanet J Rare Dis; 2021 Dec; 16(1):501. PubMed ID: 34863240
[TBL] [Abstract][Full Text] [Related]
9. Psychobehavioral factors and family functioning in mucopolysaccharidosis: preliminary studies.
do Valle DA; Bara TDS; Furlin V; Santos MLSF; Cordeiro ML
Front Public Health; 2024; 12():1305878. PubMed ID: 38327584
[TBL] [Abstract][Full Text] [Related]
10. Quantifying medical manifestations in Hurler syndrome with the infant physical symptom score: associations with long-term physical and adaptive outcomes.
Ahmed A; Rudser K; King KE; Eisengart JB; Orchard PJ; Shapiro E; Whitley CB
Mol Genet Metab; 2022 May; 136(1):22-27. PubMed ID: 35304037
[TBL] [Abstract][Full Text] [Related]
11. Cognitive and behaviour profiles of children with mucopolysaccharidosis Type II.
Crowe L; Yaplito-Lee J; Anderson V; Peters H
Cogn Neuropsychol; 2017 Sep; 34(6):347-356. PubMed ID: 29210605
[TBL] [Abstract][Full Text] [Related]
12. The effectiveness and cost-effectiveness of enzyme and substrate replacement therapies: a longitudinal cohort study of people with lysosomal storage disorders.
Wyatt K; Henley W; Anderson L; Anderson R; Nikolaou V; Stein K; Klinger L; Hughes D; Waldek S; Lachmann R; Mehta A; Vellodi A; Logan S
Health Technol Assess; 2012; 16(39):1-543. PubMed ID: 23089251
[TBL] [Abstract][Full Text] [Related]
13. Long-term experience with enzyme replacement therapy (ERT) in MPS II patients with a severe phenotype: an international case series.
Lampe C; Bosserhoff AK; Burton BK; Giugliani R; de Souza CF; Bittar C; Muschol N; Olson R; Mendelsohn NJ
J Inherit Metab Dis; 2014 Sep; 37(5):823-9. PubMed ID: 24596019
[TBL] [Abstract][Full Text] [Related]
14. Cerebral magnetic resonance findings during enzyme replacement therapy in mucopolysaccharidosis.
Matsubara Y; Miyazaki O; Kosuga M; Okuyama T; Nosaka S
Pediatr Radiol; 2017 Nov; 47(12):1659-1669. PubMed ID: 28733853
[TBL] [Abstract][Full Text] [Related]
15. Tracheostomy in mucopolysaccharidosis type II (Hunter's Syndrome).
Malik V; Nichani J; Rothera MP; Wraith JE; Jones SA; Walker R; Bruce IA
Int J Pediatr Otorhinolaryngol; 2013 Jul; 77(7):1204-8. PubMed ID: 23726952
[TBL] [Abstract][Full Text] [Related]
16. Treatment reduces or stabilizes brain imaging abnormalities in patients with MPS I and II.
Wang RY; Cambray-Forker EJ; Ohanian K; Karlin DS; Covault KK; Schwartz PH; Abdenur JE
Mol Genet Metab; 2009 Dec; 98(4):406-11. PubMed ID: 19748810
[TBL] [Abstract][Full Text] [Related]
17. Characterization of pulmonary function impairments in patients with mucopolysaccharidoses--changes with age and treatment.
Lin SP; Shih SC; Chuang CK; Lee KS; Chen MR; Niu DM; Chiu PC; Lin SJ; Lin HY
Pediatr Pulmonol; 2014 Mar; 49(3):277-84. PubMed ID: 23401495
[TBL] [Abstract][Full Text] [Related]
18. Intrafamilial variability in the clinical manifestations of mucopolysaccharidosis type II: Data from the Hunter Outcome Survey (HOS).
Ficicioglu C; Giugliani R; Harmatz P; Mendelsohn NJ; Jego V; Parini R
Am J Med Genet A; 2018 Feb; 176(2):301-310. PubMed ID: 29210515
[TBL] [Abstract][Full Text] [Related]
19. Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy.
Wraith JE; Scarpa M; Beck M; Bodamer OA; De Meirleir L; Guffon N; Meldgaard Lund A; Malm G; Van der Ploeg AT; Zeman J
Eur J Pediatr; 2008 Mar; 167(3):267-77. PubMed ID: 18038146
[TBL] [Abstract][Full Text] [Related]
20. Assessing the impact on caregivers caring for patients with rare pediatric lysosomal storage diseases: development of the Caregiver Impact Questionnaire.
Harrington M; Hareendran A; Skalicky A; Wilson H; Clark M; Mikl J
J Patient Rep Outcomes; 2019 Jul; 3(1):44. PubMed ID: 31338630
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
